4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
Are you considering buying penny stocks this June? Trading penny stocks has been extremely popular this year. With low prices and high volatility, the potential for rapid portfolio growth is an exciting prospect for investors to consider. Also, with a large number of penny stocks to buy, investors have a wide range of options to choose from. When building a penny stock watchlist, it’s important to be considering a few things.
First, it’s important to know that trading penny stocks can be a riskier investment than say blue chips. News, social media and market trends usually hold a great deal of influence on daily price movements. Additionally, because of their low cost, large price fluctuations are frequent. This can lead to major intraday gains, and just as big of losses. This is why doing prior research is key with all investments, and especially penny stocks.
The next thing to consider is current events. Although this may seem obvious, many investors fail to consider both micro and macroeconomic events. These could be large worldwide happenings or an industry-specific occurrence. Regardless, because penny stocks tend to be extremely volatile, these are major influences on price that should be taken into account. With biotech penny stocks, this can be even more influential.Biotech Penny Stocks in 2021
Biotech as an industry tends to be more speculative than most. When a press release is put out, a new drug approved, or something as simple as an industry presentation occurs, prices will move. These could be positive or negative price actions, but the important thing to understand is whether you’re in the know or not.
This past year there has been mostly bullish in the biotechnology industry. With the exception of the past month or two, the Coronavirus has resulted in a vastly increased focus on biotech penny stocks of all types. While companies like Moderna Inc. (NASDAQ: MRNA), Pfizer Inc. (NYSE: PFE), and Johnson and Johnson (NYSE: JNJ) are leading the blue-chip biotech wave, there are plenty of small-caps to watch as well.
The obvious choice is to look for a company with involvement in Covid. But, we’re witnessing momentum among those that do and those that do not have involvement in a vaccine or treatment. Because of this, investors should know what compounds or tech products a biotech company has in its pipeline. This is the best way to ensure either present or future momentum.4 Biotech Penny Stocks To Add To Your Watchlist
In general, the biotech industry is at the cutting edge of science. Every year more and more companies are producing novel drugs, medical devices, and research. This innovative sector thrives off of competition which is why so many look towards biotech penny stocks during times of market uncertainty.
So, while making a biotech watchlist for 2021 is difficult, it can be a profitable endeavor if done correctly. Remember; research, research, and more research. This will always be the key to finding biotech companies with forward momentum. Additionally, stay on the lookout for both company and industry-wide announcements as well as government news and regulatory measures. With all of this in mind, here are four biotech penny stocks to watch right now.
- GT Biopharma Inc. (NASDAQ: GTBP)
- Atossa Therapeutics Inc (NASDAQ: ATOS)
- Citius Pharmaceuticals Inc (NASDAQ: CTXR)
- Asensus Surgical Inc (NYSE: ASXC)
When it comes to penny stocks, the idea of a small company becoming a much more dominant force is a real hope for some. While GT Biopharma is no longer a penny stock, it wasn’t that long ago when it was trading below $5 a share. If you look back over the last year, at one point, GTBP shares were trading below $2.
What began as a plan to build a viable treatment pipeline with therapeutic potential has evolved into something which has brought about bullish interest from both traders and analysts alike. Roth Capital, B. Riley, and HC Wainwright all have Buy ratings on GT Biopharma and price targets ranging from $21 to $25 for the former penny stock. The company also received notification that it would get added to the Russell 2000® Index later this month.What To Watch With GT Biopharma
The core focal point right now is on the company’s novel treatment technology, TriKE. It’s been designed to enhance the cancer-killing abilities of a patient’s immune system’s natural killer or “NK” cells. GT Biopharma’s lead treatment candidate, GTB-3550, has shown considerable progress over the last few months. In a recent update, the company highlighted several key findings of its current Phase I/II study. The treatment is initially in use by patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Recent results from the first 9 patients in the study showed GTB-3550’s ability to reduce up to 63.7% bone marrow blast levels and showed no signs of adverse side effects.
But it isn’t just a one-treatment biotech company. GT Biopharma’s other solid tumor TriKEs are being designed to target cancers expressing HER2 (GTB-6550), PD-L1 (GTB-4550), and B7H3 (GTB-5550). Multiple cancer treatments will be evaluated in indications that include breast, lung, gastric, colorectal, and ovarian. With bullish ratings, strong progress in its current phase trial as well as more treatments on the horizon, GTBP stock has been one of the biotech names to know about this year.Atossa Therapeutics Inc (NASDAQ: ATOS)
The first penny stock on the list is Atossa Therapeutics. This company is a clinical-stage biopharmaceutical company that aims to research and develop leading medicines in the fields of oncology and infectious disease. Currently, ATOS focuses its efforts on solutions for breast cancer and COVID-19. Both of these issues have major media attention as well as an impact on the human condition, making them heavily funded research areas in the biotech industry.
Recently ATOS has received phase 2 initiation approval from the Swedish Medical Product Agency for its oral Endoxifen. This drug targets mammographic breast density (MBD), to reduce and eradicate potential tumors. MBD affects millions worldwide and can reduce the effectiveness of mammograms.What To Watch With Atossa
Doctors around the world depend on mammogram studies to detect cancer through breast density. With a drug such as Endoxifen, it would increase the ability for earlier diagnosis, which in turn could reduce breast cancer incidence.
“This is a critical milestone in the development of our oral Endoxifen. We now plan to commence the study as soon as restrictions for COVID-19 in Stockholm allow and we are encouraged that daily and weekly average COVID-19 cases have been steadily declining in Sweden over the past six weeks…If this trend continues, we expect to initiate the study in the next quarter. We have also received useful input from the MPA about the development path for Endoxifen.”Steven Quay, CEO of ATOS
This is a large breakthrough for the company and considering the incidence of breast cancer around the world, Endoxifen could be a big deal moving forward. Investors should stay up to date with any news regarding this compound, as it is Atossa’s flagship product. However, it does have a sizable pipeline that includes a Covid-19 nasal spray treatment known as AT-301. Not only is its pipeline large, but it is also quite broad in the ailments it treats. Considering all of this, will ATOS stock be on your watchlist moving forward?Citius Pharmaceuticals Inc (NASDAQ: CTXR)
The next biotech company that could be worth keeping an eye on is Citius Pharmaceuticals Inc. Citius is a pharmaceutical company that specializes in critical care products. Specifically, CTXR operates in the development and commercialization of products for anti-infectives used in many medical settings. Its flagship product right now is Mino-Lok. This is an antibiotic in use for the treatment of catheter-related bloodstream infections.
In addition to this, CTXR is in the process of producing several other compounds. This includes Mino-Lok, CITI-002, an anti-inflammatory coupled with an anesthetic for pain reduction in patients with hemorrhoids; and CITI-101, a bio-absorbable film that contains minocycline and rifampin in order to reduce inflammation and microbial colonization.What To Watch With Citius
Its broad range of products helps to offer Citius a larger potential market share of the biotech industry. And, right now Mino-Lok is in the later part of a Phase 3 trial, meaning that it could be close to commercialization.
With biotech penny stocks or any biotech stock for the matter, commercialization is the key to revenue and long-term success. Either a company gains product approval and begins producing it, or it licenses out an approved product to other companies. These are the main driving sources of revenue for most companies in the biotech industry.
Up more than 7% at midday, CTXR is showing a lot of bullish potential right now. In the past month, shares of CTXR stock have shot up by over 40%, and in six months, by more than 160%. Whether these numbers make Citius Pharmaceuticals worth watching, however, is up to you.Asensus Surgical Inc. (NYSE: ASXC)
Up by as much as 7% at midday, ASXC is a penny stock that we’ve covered numerous times in the past few months. Big news dropped when the company announced it would be joining the Russell 2000 and Russell Microcap Indexes only a few days ago. This will occur after the market opens on June 28th.
“We’re thrilled to be a part of the Russell 2000 Index and believe that our inclusion will increase our visibility and exposure to investors. This milestone is a testament to our hard work to create value for our stockholders through our strategy and bring the Senhance System’s transformative technology to surgeons, hospitals, and patients globally.”Anthony Fernando, CEO of Asensus
For some context, Asensus is a biotech company working on producing digitized interfaces between surgeons and patients. This is known as Performance-Guided Surgery. The company puts to use the principles of Digital Laparoscopy in its flagship product, the Senhance System. This system is powered by its Intelligent Surgical Unit or ISU.What To Watch With Asensus
This system utilizes machine vision, AI, and deep learning to completely redesign the way that common surgeries occur. And, its system allows for less error, better surgical outcomes, and more economical procedures.
While this is still a new technology, Asensus is working hard to commercialize it as quickly as possible. Considering the stark and always changing need for new surgical methods, the Senhance System is a welcomed advancement in the medical field.
Obviously, widespread adoption will take time, money, and a commitment from doctors, hospitals, and more, it looks like it could be a game-changer for the industry. With all of these exciting announcements in mind, will ASXC be on your list of penny stocks to watch?Which Biotech Penny Stocks Are You Watching?
At the end of the day, finding the best biotech penny stocks to watch all comes down to knowing where to look. With the internet at all of our fingertips, locating value in the biotech industry can be easy.
But as mentioned before, investors need to do the proper research to find which companies may have either short or long-term value. This involves knowing what’s in its pipeline and how close those compounds or technologies are to approval. Considering all of this, which biotech penny stocks are you watching?
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP) Midam has been paid $150,000 for a period from March 1, 2021, to April 1, 2021. This compensation is payment 1 of 12 as part of a 12-month agreement between Midam Ventures LLC & GT Biopharma (GTBP), for a period from March 1, 2021, to February 28, 2022. Midam Ventures LLC expects to be paid $150,000 per month for a total of 12 months by GT Biopharma (GTBP). Midam has been paid an additional $150,000 for a period from April 2, 2021, to May 1, 2021. This compensation is payment 2 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from May 2, 2021, to June 1, 2021. This compensation is payment 3 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from June 2, 2021, to July 1, 2021. This compensation is payment 4 of 12 as part of the Agreement. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during, or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click here for full disclaimer.